G H RECEPTOR (GHR) is a transmembrane protein that
binds GH with high affinity and specificity. Expression of the receptor is a requirement for cellular responsiveness to GH. The primary transcript that generates the GHR mRNA can undergo alternative processing to produce several related mRNAs, including transcripts that encode the circulating GH-binding protein (GHBP) and a truncated GHR that inhibits normal cellular responses to GH in vitro. In addition, the use of alternative promoters and transcription start sites in the GHR gene-regulatory region generates transcript forms that differ only in the 5Ј-untranslated region (5Ј-UTR). This article will review the transcripts originating from the GHR gene. The introduction will address the expression of GHR and GHBP, the major transcripts of the gene. The second section describes the structure of the GHR gene. The third section describes the types of alternative transcripts produced by the gene, the alternative processing mechanisms that produce them, and the biological functions of their protein products. The final section suggests future studies on the expression and function of alternative GHR transcripts.
Normal postnatal growth in mammals requires the presence of GH, a M r 22,000 polypeptide hormone released primarily from the anterior pituitary gland (reviewed in Ref. 1) . GH is bound with high affinity and high specificity by two proteins, the GHR and GHBP. The receptor is associated with the cell membrane of GH target tissues and mediates the somatogenic and metabolic effects of the hormone. The binding protein is found in the serum and forms complexes with circulating GH. Although the exact biological role of the binding protein has not yet been determined, it has been shown to enhance the growth-promoting effects of GH in vivo (2, 3) , probably by increasing the half-life of GH in the circulation (4).
GHR in most species has a M r of 100,000 -130,000, although smaller and larger molecular weights have been reported (reviewed in Ref. 5). To date, the amino acid sequence of the GHRs from nine species have been published. These species are the human and rabbit (6), mouse (7), rat (8, 9), bovine (10), sheep (11), pig (12), chicken (13), and monkey (14) . In all nine species, the amino acid sequence was deduced by sequencing a cDNA clone of the receptor mRNA.
Based on the deduced amino acid sequences, GHR is predicted to be a single-pass transmembrane protein approximately 620 amino acids in length; the exact number of amino acids varies slightly from species to species. The receptor is initially synthesized as a preprotein roughly 640 amino acids in length, containing a short signal peptide at its amino terminus for direction of the receptor to the cell surface. The mature receptor (after removal of the signal peptide) has an extracellular hormone-binding domain of approximately 245 amino acids (depending on the species) at its N terminus, a hydrophobic transmembrane domain of 24 amino acids, and an intracellular signaling domain of approximately 350 amino acids at its C terminus. Figure 1 compares the sizes of the mature GHRs from the nine species and lists their percent homology to human GHR.
GHBP has been detected in the rabbit (15, 16), human (17, 18), monkey (14, 19), mouse (7, 20), rat (8, 16, 21, 22), goat, dog, cat (19, 23), bovine, horse, pig, sheep, chicken, goose, turkey (24, 25), turtle (26), and guinea pig (27) . The reported M r of the binding protein ranges from 27,500 (24) to 85,000 (18), depending on the species and the method of analysis. GHBP is found in the circulation (reviewed in Ref. 28 ), intracellularly (29, 30) , and associated with cell membranes (31, 32). Under normal physiological conditions, an estimated 40 -50% of circulating GH in humans is complexed with the GHBP (33, 34). The exact percentage bound fluctuates diurnally between 10% and 80% due to pulsatile release of GH from the pituitary (35). In nonpregnant mice, estimates of the percent bound GH in serum have ranged from 20% (36) to 50% (37). This percentage increases to more than 90% during pregnancy due to an up-regulation of GHBP relative to GH.
Although the substantial amount of GH in serum bound by GHBP, the intracellular presence of GHBP, and cell mem-brane GHBP all suggest a role of GHBP in the GH axis, investigations of GHBP function have led to conflicting proposals regarding its effects on GH action. Studies have demonstrated that GHBP prolongs the existence of GH in circulation (36, 38 -40), suggesting that GHBP might potentiate GH action by prolonging the availability of GH to target tissues. Consistent with this proposed GHBP function, injection of a GH/GHBP mixture into rats was more effective at promoting growth than injection of GH alone (2) . However, GHBP has been shown in vitro to inhibit binding of GH to several cell types and to attenuate the cellular response to GH (41-43). These inhibitory actions are believed to occur through competition between GHBP and GHR for the hormone. It has recently been proposed that the two seemingly contradictory effects of serum GHBP on GH action may both have biological relevance (44). The authors suggest that the relative concentrations of serum GH and GHBP or the physiological state of the animal might dictate whether the inhibitory or the potentiating effect of serum GHBP will predominate. The function(s) of intracellular and membrane-associated GHBP remain entirely unclear.
Several early studies suggested that the binding protein is either identical, or highly homologous, to the extracellular domain of the receptor. Antibodies raised against the extracellular portion of the receptor cross-reacted with the binding protein (45). Protein sequencing of the N termini of the rabbit receptor and the binding protein showed identical amino acid sequences (6). Recent studies (reviewed in Refs. 4 and 46) have explained these findings by demonstrating that GHBP is derived from GHR either by proteolytic cleavage of the receptor's extracellular domain or by alternative splicing of the GHR primary transcript (GHBP generation will be addressed in greater detail below). Both mechanisms produce GHBP with a hormone-binding domain that is essentially identical to that of GHR. One or the other of these two methods of GHBP generation appear to be used exclusively in some species, while both methods are used in others. The number of amino acids present in circulating GHBP have been best characterized in the rabbit, rat, and mouse. The sizes of the GHBPs in these three species are compared in Fig. 1 .
GHR transcripts have been detected in a variety of tissues including liver, muscle, kidney, lung, mammary gland, placenta, and adipose tissue, with the highest level of expression being in the liver (reviewed in Ref. 47) . As determined by Northern analysis, the major mRNA that encodes the fulllength receptor is approximately 4.6 kb in length, although the exact size varies slightly from species to species. The smallest reported GHR mRNA is the 3.9-kb mouse transcript (7) and the largest is the 5.0-kb monkey transcript (14). Table  1 compares the size of the full-length GHR transcript from nine species. In all nine species the major GHR transcript is more than twice as large as the minimum 1.9 kb necessary to encode the 640-amino acid receptor/signal peptide molecule. The majority of the "excess" size of the GHR mRNA is due to the presence of an approximately 2-kb 3Ј-untranslated region (3Ј-UTR) in the transcript (6, 58) . Although the specific function of the large 3Ј-UTR in the GHR transcript has not been investigated, 3Ј-UTRs in general are thought to affect degradation rates of mRNAs and perhaps also initiation of translation (59, 60) . 
II. The GHR Gene
The GHR gene has been cloned and characterized in two species, the human (61, 62) and the mouse (63) (64) (65) (66) . Figure 2 compares the structure and size of the human and mouse GHR genes. Analysis of human GHR mRNA 5Ј-ends by RT-PCR followed by sequencing of the products has shown eight distinct 5Ј-UTRs (5Ј-UTRs V1-V8) to be present (see Section III.A below). The exons encoding four of the 5Ј-UTRs have been cloned (exons V1, V4, V7, and V8 in the human gene diagram). These exons are considered alternative first exons of the GHR gene. After the alternative first exons, there are 9 coding exons (exons 2-10). Exon 2 encodes the final 11 bp of the 5Ј-UTR sequence, the 18-amino acid signal sequence, and the first 5 amino acids of the extracellular hormone-binding domain. Exons 3-7 together encode the majority of the extracellular hormone-binding domain. Exon 8 encodes the final 3 amino acids of the hormone-binding domain, the 24-amino acid hydrophobic transmembrane domain, and the first 4 amino acids of the intracellular domain. Exons 9 and 10 together encode the remaining 346 amino acids of the intracellular domain. Exon 10 also encodes the 2-kb 3Ј-UTR of the transcript.
Two distinct 5Ј-UTRs, designated L1 and L2, have been found in mouse GHR transcripts by RT-PCR and cDNA sequencing. The exons encoding L1 and L2 are alternative first exons in the mouse GHR gene. After the alternative first exons, there are eleven coding exons, which are (in order) exons 2-4, exon 4B, exons 5-7, exon 8A, and exons 8 -10. The nine exons with only numeric designations (exons 2, 3, 4, 5, 6, 7, 8, 9, and 10) are homologous in size and sequence to the human GHR-coding exons with the same designations. For example, exon 8 in both the human and the mouse genes encodes the 24-amino acid transmembrane domain, as well as the final 3 amino acids of the extracellular domain and the first 4 amino acids of the intracellular domain. The two remaining exons, exon 4B and exon 8A, encode amino acid segments that do not have homologs in human GHR.
Exon 4B encodes an 8-amino acid segment (glu-ser-glnarg-gln-ala-ala-arg) of the mouse GHR extracellular domain. None of the other species for which GHR has been sequenced, including the rat, have amino acids between the exon 4 and exon 5-encoded amino acids. Although the unique nature of the mouse 8-amino acid segment raises questions about its possible effects on GH binding, no investigations have directly addressed this topic. Studies investigating binding of GH to GHR in the human, however, have provided clues regarding the possible function of the exon 4B amino acids. X-ray crystallography of human GHR extracellular domain binding with the GH molecule (67) showed that the amino acids encoded by the exon 4/exon 5 splice junction do not interact with the GH molecule. This suggests that the 8-amino acid segment of mouse GHR would also not directly participate in binding the GH molecule. Mutational analysis of the human GHR (68) , however, has shown that conversion of the last 2 amino acids of exon 4 (Arg 70 and Arg 71 ) or the fifth amino acid of exon 5 (Trp 76 ) to alanine reduced GH binding by 2-fold, 2.7-fold, and 2.5-fold, respectively. Together, these results suggest that the region encoded by the exon 4/exon 5 splice junction in the human, while not directly involved in binding GH, is important for proper folding of the GHR extracellular domain. Whether the same results apply to the mouse exon 4B amino acids remains to be clarified through mutagenesis and x-ray crystallography studies of the mouse extracellular domain.
Exon 8A also has no homolog in the human GHR gene. It is located in the 2-kb segment separating exons 7 and 8. Exon 8A encodes the C-terminal hydrophilic domain of mouse GHBP and the 3Ј-UTR of the GHBP transcript. Exons 7, 8A, and 8 can undergo alternative splicing to produce the GHR and the GHBP transcripts (see Section II.B below). Splicing of exon 7 to exon 8A generates the 1.2-kb GHBP transcript, while splicing of exon 7 to exon 8 generates the 4.0-kb GHR transcript.
The chicken GHR gene has been partially characterized by genomic Southern blotting and sequencing of selected exons (58) . Although smaller in overall size due to shorter introns, the exon structure appears to be similar to that of the human GHR gene (Fig. 3) . The coding exons of the chicken GHR gene were numbered to correspond to the homologous exons in the human GHR gene. Exon 3 in the human GHR gene, however, does not have a homolog in the chicken GHR gene. Consequently, exon 4 follows exon 2 in the map of the chicken GHR gene. Studies of human GHR have shown that the amino acids encoded by exon 3 are not critical for GH binding (69 -71) . There have been two reported 5Ј-UTRs found in chicken GHR transcripts, but the exon(s) encoding them have not yet been cloned.
III. GHR Transcript Heterogeneity
Heterogeneity in the size and sequence of GHR transcripts has been reported in all species but one, the pig. GHR transcript heterogeneity is generated by several types of alternative processing of the primary transcript, including exon skipping, retention of introns, alternative splice-acceptor sites within exons and introns, alternative transcription start sites, and the use of alternative polyadenylation sites. In some cases alternative processing generates transcripts that differ significantly in size from the 4.6-kb GHR transcript. In cases where the transcript sizes of a species differed among publications, the following reporting method was used. All transcripts with sizes that agreed within 0.3 kb were considered to be the same transcript, and an average of the reported sizes is given as the transcript size in the table. Transcripts with sizes that differed by greater than 0.3 kb were considered separate transcripts and are listed individually.
a Transcripts only observed during pregnancy.
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These alternative transcripts can be visualized as separate and distinct bands by Northern analysis. Transcripts smaller than the major GHR transcript have been detected by Northern analysis in various tissues of the human (49), chicken (13, 56), rabbit (72) , mouse (7), rat (8, 73), monkey (14), and sheep (11, 54). Transcripts larger than the major GHR transcript have been detected in pregnant sheep and mice (37, 54). Table  1 lists the sizes of GHR transcripts detected by Northern analysis.
In cases where the transcript size is not significantly altered, restriction analysis and cDNA sequencing have been used to detect alternative GHR transcripts. For example, sequencing of bovine GHR cDNAs, which appear as a single band by Northern analysis, has revealed GHR transcript heterogeneity in this species as well (74) . Regardless of the actual size of the transcript, the terms "full length" and "major" GHR transcript will be used to indicate transcripts that encode the entire GHR, including complete extracellular, transmembrane, and intracellular domains. For the purposes of this review, GHR transcripts generated by alternative processing will be divided into three categories: 1) transcripts with 5Ј-UTR heterogeneity, 2) transcripts that encode deletions or truncations of the receptor transmembrane or intracellular domains, and 3) transcripts that encode deletions in the receptor hormone-binding domain.
A. 5Ј-UTR heterogeneity
Heterogeneity in the 5Ј-UTR of GHR transcripts was observed in the first GHR cDNAs to be cloned and sequenced, those of the rabbit and human (6). Of the six human clones that were sequenced, five had distinct 5Ј-UTRs. All three of the rabbit clones had distinct 5Ј-UTR sequences. Within each species, the 5Ј-UTRs were identical for the first 11 bases upstream of the initiating AUG codon but diverged in sequence beginning at the 12th base. Human GHR exon 2 encodes the final 11 bases of the 5Ј-UTR as well as the first 23 amino acids of the coding region. The point of divergence of the human and rabbit 5Ј-UTR sequences was therefore exactly coincident with the 5Ј-boundary of exon 2, strongly suggesting that the sequence divergence is produced by splicing of alternative 5Ј UTR-encoding exons to exon 2.
Subsequent studies identified two distinct 5Ј-UTRs in GHR transcripts of the sheep (11, 52), chicken (58), cow (10, 74), and mouse (75) , five 5Ј-UTRs in the rat (76) , and eight 5Ј-UTRs in the human (77) . One of the eight human 5Ј-UTRs (designated 5Ј-UTR V5) was identical in sequence to the intron immediately upstream of exon 2 in the human GHR gene (61) and therefore might represent a partially spliced form of the GHR transcript instead of a true alternative first exon. Another of the human 5Ј-UTRs (V3) was found in three distinct forms, designated V3a, V3b, and V3c. The V3c form had a 93-bp internal deletion compared with the other two forms, while V3b contained a divergent 5Ј-sequence compared with the other two V3 sequences. Most of the GHR 5Ј-UTRs contain one or more upstream AUG codons. AUG codons occur in less than 10% of all eukaryotic 5Ј-UTRs but are found at much higher frequencies in the 5Ј-UTRs of protooncogenes, growth factors, and cell surface receptors (reviewed in Ref. 78) . Upstream AUG codons occurring as part of the strong translation-initiating consensus sequence A/GNNAUGG (79) have been shown to suppress translation at the downstream translation initiating AUG (reviewed in Ref. 80) . Although the majority of GHR 5Ј-UTR AUG codons are not found in strong start sequences and therefore are not predicted to influence translation efficiency, their frequency remains a curious feature of GHR 5Ј-UTRs. Table 2 lists the known GHR 5Ј UTRs by species and indicates their name designations, their homology to the 5Ј-UTRs of other species, and the number of upstream AUG codons.
In all species with multiple GHR 5Ј-UTRs, the variants diverged in sequence a few bases (9 -12 bp, depending on the species) upstream of the translation-initiating AUG codon, consistent with splicing of alternative first exons to the second exon of the GHR gene. Further evidence that GHR 5Ј-UTRs were encoded by individual exons was the observation that certain 5Ј-UTRs were associated with GHR transcripts of specific tissues, most notably the liver. Rat 5Ј-UTR V2, sheep 5Ј-UTR 1A, and human 5Ј-UTR V1 are all expressed exclusively in the liver, whereas other rat and sheep 5Ј-UTRs are expressed in a variety of tissues (11, 52, 62, 76, 82) . Mouse 5Ј-UTR L1 and bovine 5Ј-UTR 1A, while not expressed exclusively in the liver, do have higher levels in the liver than in other tissues surveyed (74, 75) . Table 3 lists the tissue expression patterns of the mouse, rat, human, sheep, and bovine alternative 5Ј-UTRs.
Although the hypothesis that GHR 5Ј-UTRs are encoded by separate exons is strongly supported by the findings that the UTRs are expressed in a tissue-specific manner and that the point of sequence divergence is identical to the 5Ј-boundary of exon 2, it was only through cloning of the 5Ј-UTRencoding regions of the gene itself that this hypothesis has been confirmed. Genomic cloning, sequencing, and reporter gene studies of the GHR-regulatory region have been undertaken in the sheep, cow, mouse, human, and rat.
1. The sheep. Using the two 5Ј-UTRs (1A and 1B) of the sheep GHR cDNAs as probes, sheep genomic clones containing the two alternative first exons were isolated and sequenced (52, 83) . The upstream-most of the two exons encodes 5Ј-UTR 1B and is located at least 27 kb upstream of exon 2. The region immediately upstream of exon 1B contains a CCAAT box and a GC box, the binding consensus sequences for the common transcription factors CCAAT transcription factor (CTF) and promoter specific transcription factor 1 (Sp1), as well as several less common binding consensus sequences, such as E boxes (a binding site for the muscle-specific transcription factor MyoD) and a C/EBP site, which is bound by members of the CCAAT/enhancer binding protein family of transcription factors. C/EBP sites are associated with genes expressed in the liver (reviewed in Ref. 85) . No TATA boxes were found upstream of the 1B exon. Northern analysis indicated that 5Ј-UTR 1B is expressed in liver, skeletal muscle, testes, intestine, and adrenal GHR transcripts. Lower levels of ex- Fig. 2 for an explanation of exon and intron symbols. The exons were given numerical designations to indicate homologies with coding exons of the human GHR gene. Exon 4 follows exon 2 in the diagram to indicate that the chicken GHR gene has no homolog of human exon 3. The exact locations of exons 2 and 7 were not determined. The location of these exons on the diagram is therefore an approximation. Although chicken GHR transcripts have two known alternative 5Ј-UTR sequences, the exon(s) encoding these 5Ј-UTRs have not been cloned.
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ALTERNATIVE GH RECEPTOR TRANSCRIPTSpression were detected in heart, pancreas, and bone. When ligated upstream of a luciferase reporter gene, the promoter was able to drive in vitro expression of the reporter gene in cell lines derived from human liver (HuH7 cells), human cervix (HeLa cells), and hamster ovary (CHO cells). Together, the Northern analysis and transfection studies indicated that the 1B promoter had little tissue specificity and therefore might function as the general promoter for the GHR gene in sheep.
The downstream exon encodes 5Ј UTR-1A and is located 17 kb from exon 2. In contrast to the general tissue expression of the exon 1B, Northern analysis and ribonuclease protection assay (RPA) showed that GHR transcripts with 5Ј-UTR 1A are found only in the liver (11). Several putative binding sites for factors associated with liver-specific genes were found upstream of the exon, including four C/EBP sites, two GR sites (to which the activated glucocorticoid receptor binds), and binding site for hepatic nuclear factor 5. A TATA box is present near the major transcription start site. Reporter gene constructs demonstrated that this promoter region was active in vitro in two hepatocyte cell lines. Figure 4 shows the genomic structure and splicing pattern of the two alternative first exons and summarizes the characteristics of the two sheep GHR promoters.
The sheep 1A promoter contains sequences that resemble GH-response elements found in the rat serine protease inhibitor 2.1 gene and the rat insulin I gene (86, 87) . The promoters of the two rat genes contain the binding consensus sequence (TTCNNNGAA) for STAT5, a transcription factor known to be activated by GHR (88 -91) . The STAT5-binding sequences from both rat genes were shown to confer GH responsiveness to heterologous promoters. The sheep 1A promoter contains three elements that differ from the STAT5 binding consensus sequence by a single base. Furthermore, two of the three correspond to the sequence TTCNNNTAA, an element found in the serine protease inhibitor 2.1 promoter and shown to weakly bind STAT5. In addition to the potential STAT5-binding sites, the sheep 1A promoter contains a purine-rich sequence approximately 30 bp upstream from the TATA box. The rat Spi 2.1 gene also contains a purine-rich sequence at this location which, when combined with the TATA box and surrounding sequences, conferred GH responsiveness to a heterologous promoter. Together, Each row lists by species the name designations, significant sequence homologies, and number of upstream initiation codons. The 5Ј-UTR designation column lists the names given to each of the individual 5Ј-UTRs of species. The rat 5Ј-UTRs V1 and V2 have been given multiple designations in the literature. They are identical, respectively, to rat 5Ј-UTRs type II and type I (84), BP2 and BP1 (8), L2 and L1 (31), and GHR2 and GHR1 (82) . The sequence homology column lists the 5Ј-UTRs of other species that share significant homology with the 5Ј-UTR in that row. Human 5Ј-UTR V5 is identical to the intron sequence immediately upstream of exon 2 in the human GHR gene (61) . The AUG codon column lists the number of AUG codons found in the 5Ј-UTR upstream of the GHR-coding region. Underlined numbers denote that the 5Ј-UTR contains an AUG codon in a strong translation-initiating sequence. Question marks indicate that the 5Ј-UTR sequence has not been published.
a Name is an arbitrary designation because no name has been assigned. Vol. 19, No. 5 these findings suggest GH may up-regulate its own receptor in the sheep. This conjecture is consistent with the findings that continuous GH exposure increases hepatic GH binding in the sheep (92), rat (93) , and pig (94) and is known to up-regulate GHR transcripts in the rat (82) and in the human HuH7 hepatic cell line (95).
EDENS AND TALAMANTES

Bovine.
The exon encoding bovine 5Ј-UTR 1A has been cloned and sequenced (96) . The region upstream of the exon was not analyzed for promoter function. However, the first 500 bases of this region were 94% identical in sequence to the sheep 1A promoter, leading the authors to hypothesize that it functions as the promoter for the cow GHR exon 1A.
Although the exon(s) encoding bovine 5Ј-UTR 1B have not yet been cloned, the 1B sequence shows significant sequence homology with sheep exon 1B (74) , suggesting that the associated promoters might also be similar in sequence. Consistent with the hypothesis that the bovine 1A and 1B promoters are functionally similar to the sheep 1A and 1B promoters, bovine 1A is expressed almost exclusively in the liver while bovine 1B is expressed in the liver as well as in several extrahepatic tissues.
Mouse.
Mouse GHR transcripts contain two distinct 5Ј-UTRs, designated L1 and L2 (75) . The exon encoding mouse 5Ј-UTRs L1 has been cloned and the adjacent upstream regions sequenced (63, 97) . The region upstream of exon L1 contained two TATA boxes and an C/EBP binding site, elements that the sheep liver-specific 1A promoter also contained. Binding sites for the common transcription factors, activator protein-2 (AP-2) and CTF, were also identified. Functional analysis of the putative promoter region was carried out by ligating a 3.5-kb fragment of the DNA upstream of the exon to a luciferase reporter gene and transfecting into a hepatoma cell line. Luciferase activity increased 10-fold above that of the promoterless luciferase gene, demonstrating that the sequence upstream of the exon acts as functional promoter in vitro. Deletion of portions of the 3.5-kb fragment The species and 5Ј-UTR designation are listed at the top of each column. Tissues analyzed are listed on the end of each row. White squares containing a large black circle indicate expression of the 5Ј-UTR was detected in the tissue. White squares containing a small black circle indicate expression of the 5Ј-UTR was detected at a low level compared to the other tissues in the column which expressed the 5Ј-UTR. Circles with diagonal lines indicate expression of the 5Ј-UTR was detected by PCR but not detected by Northern analysis. Black squares indicate the tissue was analyzed for expression of the 5Ј-UTR but no expression was detected. Plain white squares indicate the tissue was not analyzed for expression of the 5Ј-UTR.
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ALTERNATIVE GH RECEPTOR TRANSCRIPTSidentified two transcription enhancer elements, located at Ϫ3.4 and Ϫ3.0 kb relative to the exon, which were necessary for maximal promoter activity. The enhancer element at Ϫ3.0 kb contained a binding site for a member of the CTF/NF-1 family of transcription factors (97) . The sequence of the enhancer element at Ϫ3.4 kb did not match the binding consensus sequence of any known transcription factor. A reporter gene construct containing the Ϫ3.4 enhancer element was more than twice as active in adult rat hepatocytes as in fetal hepatocytes, while a similar reporter gene construct lacking the Ϫ3.4 enhancer element showed equivalent activity in adult and fetal hepatocytes. These results suggest the Ϫ3.4 enhancer element might play a role in the postnatal up-regulation of GHR expression (9, 11). Sequencing mouse exon L2 and the adjacent upstream region revealed two GC boxes and a CAAT box, both of which occur in the ovine 1B promoter region (66) . Also in common with the ovine 1B promoter, no TATA box was found near the transcription start site cluster. Although reporter gene analysis will be necessary to fully characterize the mouse L2 promoter, the similarities between it and the sheep 1B promoter suggest that both function as general tissue promoters for the GHR gene. The regulatory region of the mouse GHR gene is diagrammed in Fig. 4 .
Rat.
Rat GHR transcripts have five 5Ј-UTRs, designated V1-V5 (76) . Northern blot studies show that UTR V2 is expressed exclusively in the liver, and the other four are expressed in various tissues, including the liver, but at differing levels. The exon encoding 5Ј-UTR V2 and the surrounding genomic region have been cloned (82) . Sequencing upstream of the exon showed no TATA box or other binding sites for common transcription factors. However, two GR sequences, a consensus sequence that can be bound by activated glucocortocoid receptor, were found upstream of the exon. GR sequences are found upstream of the sheep GHR liver-specific promoter as well. Although no reporter gene studies were undertaken, the authors investigated the in vivo activity of the exon's promoter by using Northern analysis and RPAs to quantitate the expression of the liver-specific 5Ј-UTR as a percentage of total GHR transcripts. They found that 30% of the liver GHR transcripts in females contain the liver-specific 5Ј-UTR V2, while in males, only 2% of the liver GHR transcripts contain 5Ј-UTR V2. Removal of the gonads caused the percentage of GHR transcripts containing 5Ј-UTR V2 to rise to 7% in males and to fall to 16% in females. Infusion of exogenous GH to males in a manner that mimics the female GH secretion pattern caused a rise in expression to 17%. Together, these data indicate that the 5Ј-UTR V2 is expressed in the liver in a sexually dimorphic manner and suggest that the sex hormones and GH secretion pattern play a major role in determining the level of its expression.
The regions of the rat GHR gene encoding 5Ј-UTRs V1, V3, V4, and V5 have not yet been cloned. However, a model of the rat GHR gene regulatory region consistent with RPA, cDNA cloning, and genomic Southern blotting data has been proposed (76) . The cDNA cloning studies showed that 5Ј-UTRs V3, V4, and V5 all begin with an identical 25-bp sequence. Downstream of this 25-bp segment the sequences diverge and become unique for 22 bp (V3), 101 bp (V4), and 175 bp (V5). Exactly 9 bp before the initiating AUG of the Vol. 19, No. 5 coding region, the 5Ј UTR sequences reconverge. These results suggested to the authors that the 25-bp segment common to 5Ј-UTRs V3, V4, and V5 might be encoded by a separate upstream exon. According to this model, the "common 25-bp" exon is spliced to downstream exons that encode the unique segments of 5Ј-UTRs V3, V4, and V5. These exons are, in turn, spliced to the 5Ј-end of exon 2, which includes the final 9 bp of the rat 5Ј-UTR sequence (Fig. 5) . Although in the simplest version of this model the common 25-bp sequence and the unique segments of 5Ј-UTRs V3, V4, and , and V5. The exons labeled V5, V4, and V3 encode the unique sequences of these three 5Ј-UTRs. Exons labeled V2 and V1 encode 5Ј-UTRs V1 and V2. Exon 2 encodes the final 9 bp of the 5Ј-UTR and the beginning of the GHR-coding region. All introns are of unknown length. Arrows represent promoter regions. A, Simple model of the GHR-regulatory region. The 25-bp exon can be spliced to exons V5, V4, and V3, which are spliced to exon 2. Exons V2 and V1 are spliced to exon 2 without splicing to the 25-bp common exon. In this model exons V1, V2, and 25 bp are each associated with a distinct promoter. B, Three models to account for the short form of the 5Ј-UTR V4 observed by RPA studies. The short form of the 5Ј-UTR may be generated by 1) exon skipping if the unique portion of the V4 sequence is composed of 2 or more exons (shown as V4A and V4B in the diagram), 2) use of an an internal splice donor or splice acceptor site (splice donor shown in diagram) in exon V4, or 3) use of a transcription start site in exon V4.
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October, 1998 ALTERNATIVE GH RECEPTOR TRANSCRIPTSV5 are each encoded by single exons, the cloning studies did not rule out that any or all of these segments might be encoded by multiple exons. In support of a more complex version of the model, RPA studies using a probe containing the 5Ј UTR V4 sequence produced a 135-bp band corresponding to full-length 5Ј-UTR V4 and a smaller band corresponding to 71 bp of 5Ј-UTR V4 sequence. The smaller band could be generated by any one of at least three forms of alternative processing: 1) The unique portion of the V4 sequence could be composed of 2 exons (V4A and V4B in Fig.  5 ). Inclusion of both V4-unique exons generates full-length 5Ј-UTR V4. Skipping either exon V4A or V4B deletes a portion of the 5Ј-UTR V4 sequence.
2) The single exon encoding the V4-unique sequence could contain an internal splice donor or splice acceptor site. Use of the internal site generates the smaller 5Ј-UTR V4. Use of the terminal splice donor/ splice acceptor site generates full-length 5Ј-UTR V4. 3) Exon V4 could contain a functional transcription start site. Use of this start site deletes the 25-bp common sequence and the 5Ј-portion of exon V4 from the 5Ј-UTR sequence. Sequencing of all V4 variants and the regions of the rat GHR gene encoding them will be necessary to determine the mechanisms that generate the observed heterogeneity. Human 5Ј-UTR V3 was also found to exist in multiple forms (77) , indicating that heterogeneity within an individual GHR 5Ј-UTR is not limited to the rat. To further investigate the structure of the rat GHR generegulatory region, Southern blots of rat genomic DNA were probed with labeled fragments corresponding to exon 2 and 5Ј-UTRs V1-V5. The exon 2, V1, and V2 probes all apparently hybridized to a single 4.5-kb EcoRI band, suggesting that the V1 and V2 exons are located no more than 4.5 kb upstream of exon 2. This result was unexpected because a 15-kb section of rat genomic DNA, analyzed during the genomic cloning of exon V2, contained no exons other than V2 (82) . Furthermore, the mouse homologs of rat V2 and V1 have been mapped much further than 4.5 kb upstream of exon 2 (15 kb and Ͼ26 kb upstream of exon 2, respectively) (Ref. 63 and our unpublished observations). One possible explanation for this discrepancy is that the single 4.5-kb EcoRI fragment indicated by Southern blotting to contain exons 2, V1, and V2 is, in reality, three EcoRI fragments of nearly equal size, with each fragment containing only one of the exons. In support of this model, the genomic cloning of exon V2 showed that the exon was located on a 5.0-kb EcoRI fragment, similar in size to the 4.5-kb fragment reported to contain exons V1, V2, and 2.
Probes corresponding to 5Ј-UTRs V3, V4, and V5 hybridized to EcoRI restriction fragments distinct in size from the 4.5-kb fragment proposed to contain exons V1, V2, and 2. These results indicate that exons V3, V4, and V5 are located further upstream than the V1 and V2 exons. Although there is no EcoRI restriction site within the V4 sequence, the probe corresponding to 5Ј-UTR V4 hybridized with two EcoRI fragments, whereas a V4 probe from which the 25-bp common sequence had been removed (leaving only the V4-unique sequence) hybridized to a single EcoRI fragment. These results are consistent with the common 25-bp segment being encoded by a separate exon than the V4-unique segment.
Human.
Human GHR transcripts have eight alternative GHR 5Ј-UTRs, designated V1-V8 (77) . Exons encoding UTRs V1, V4, V7, and V8 have been cloned (62) . The four exons are clustered within a 2-kb section of genomic DNA. The distance between these exons and exon 2 was not established. Northern analysis showed that 5Ј-UTR V1 was expressed exclusively in the liver. The sequence 200 bases upstream of exon V1 contained a TATA box but no other binding sites of known transcription factors. A reporter gene containing 2 kb of DNA upstream of the exon V1 was able to increase luciferase expression 20-fold above that of the promoterless luciferase gene when transfected into a hepatocyte cell line, demonstrating that the region upstream of the liver-specific exon is a functional promoter in vitro. Expression of 5Ј-UTRs V2-V8 was not detected by Northern analysis in the liver or any of 19 other tissues examined. This was an unexpected result for two reasons. All eight of the human 5Ј-UTRs were originally cloned from a liver cDNA library (6, 77) and therefore detection of all eight was expected in the liver. Second, GHR transcripts had been detected by RT-PCR in several tissues (98) , including kidney, pancreas, heart, testis, ovary, lung, and the intestine, tissues that did not express any of the eight known GHR 5Ј-UTRs as detected by Northern analysis. The apparent contradiction in these studies might indicate that extrahepatic GHR transcripts contain novel (uncharacterized) 5Ј-UTRs, or it might simply reflect the different sensitivities of RT-PCR and Northern analysis.
6. Conclusion. In summary, GHR transcripts in all species studied except the pig and the monkey are known to contain alternative 5Ј-UTRs. The exons encoding 10 of the 5Ј-UTRs (2 from sheep, 1 from bovine, 2 from mouse, 4 from human, and 1 from rat) have been cloned from genomic DNA, and in each case each 5Ј-UTR was shown to be encoded by a separate exon. Reporter gene studies and Northern analysis suggest that the 5Ј-UTR exons are associated with unique promoters. In each species in which 5Ј-UTR expression has been studied, one of the 5Ј-UTRs displayed exclusive or elevated activity in the liver. The purpose of multiple 5Ј-UTRs in the GHR transcripts is not clear at this time. One possibility is that they serve a regulatory role by differentially affecting the translational efficiency of the mRNAs. Another possibility is that the complexity of the tissue and physiological regulation of GHR transcription necessitates multiple promoters and, as a consequence, the expression of multiple 5Ј-UTR sequences.
B. Deletions and truncations of the transmembrane or intracellular domain
Sequence heterogeneity in the GHR transcript's coding region, unlike the heterogeneity in the 5Ј-UTRs, has the potential to directly alter the receptor's amino acid sequence and, therefore, its biological properties and function. Transcripts with altered or deleted transmembrane and intracellular domain-encoding regions are of particular interest because these domains are associated with two central functions of the receptor, integration into target tissue cell membranes and signal transduction. In this section, deletions of the transmembrane domain will be reviewed first, followed by truncations of the intracellular domain.
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Deletions of the transmembrane domain.
a. Mouse. The first evidence for a change in the function of GHR due to alternative processing of the transcript was the finding that in the mouse, the circulating GHBP is produced by alternative splicing of the primary GHR transcript (7). Early studies had shown that the M r of the circulating mouse GHBP and GHR were 42,000 and 103,000, respectively (99, 100) , and that the two proteins were immunologically similar (99) . Northern blots of mouse liver RNA revealed two transcripts of 3.9 kb and 1.2 kb, which hybridized to a GHR probe (50) . Cloning of the cDNAs showed the transcripts were identical in sequence for the first 899 bp, after which point they diverged (7). Based on the predicted amino acid sequence, both transcripts encoded an identical GH-binding domain but diverged in sequence beyond this point. The 3.9-kb transcript's GH-binding domain is followed by a 24-amino acid hydrophobic transmembrane domain and a 350-amino acid intracellular domain, indicating that it encodes the full-length GHR. The 1.2-kb transcript's GH-binding domain is followed by a 27-amino acid hydrophilic C-terminal domain. The smaller size of the 1.2-kb transcript's predicted protein product and its lack of a transmembrane domain suggested that it encoded the mouse serum GHBP. Transfection of a cDNA clone encoding the 1.2-kb transcript into the Chinese hamster ovary (CHO) cell line and the monkey kidney COS-7 cell line resulted in high levels of GH-binding activity in the media (5). An antibody was raised against a synthetic peptide containing the 27-amino acid C-terminal domain encoded by the 1.2-kb transcript (101). The antibody was able to immunoprecipitate GHBP from serum, confirming that mouse GHBP is the translation product of the 1.2-kb transcript. Although the absolute identity of the first 899 bp of the transcripts strongly suggested the 3.9 kb and the 1.2 kb mRNAs arise by alternative splicing of a single primary transcript, the possibility that the two transcripts originated from two highly related genes was not ruled out.
Experimental evidence confirming the alternative splicing hypothesis was obtained when the region of the mouse GHR gene containing exons 7 and 8 was cloned (64, 65) . An exon encoding the 27-amino acid hydrophilic C terminus and the 3Ј-UTR of the GHBP transcript was discovered in the 2-kb region between exons 7 and 8. The GHBP-specific exon has no homolog in the human GHR gene. To indicate that the exon follows exon 7 while differentiating it from the transmembrane domain-encoding exon 8, the GHBP-specific exon has been designated exon 8A. Figure 6 diagrams the portion of the mouse GHR gene containing exons 7, 8A, and 8. The 1.2-kb GHBP transcript contains coding exons 2-7 spliced to exon 8A. The GHR-specific exons 8, 9, and 10 are absent in the GHBP transcript. The 4.0-kb GHR transcript contains coding exons 2-7 spliced to exons 8, 9, and 10. Exon 8A does not appear in the GHR transcript. Figure 7 diagrams potential alternative processing pathways for generation of GHR and GHBP transcripts in mice. Splicing of exon 8 to exon 7 removes the GHBP-specific exon, committing the primary transcript to generate GHR mRNA (upper pathway in Fig. 7) . At least two distinct processing pathways can eliminate the ability of the primary transcript to produce GHR mRNA, ostensibly committing it to produce the GHBP transcript. Splicing of exon 8A to exon 7 renders the primary transcript unable to produce GHR mRNA by making exon 7 unavailable for splicing to exon 8 and by placing the in-frame stop codon of exon 8A upstream of the GHR-specific exons. This step is followed by cleavage and polyadenylation of the transcript in the 3Ј-UTR sequence of exon 8A (lower left pathway in Fig. 7) . For the purposes of this review, this pathway will be referred to as the S/C (splicing before cleavage) GHBP pathway. Alternatively, the nascent transcript may become committed to GHBP mRNA production by first undergoing cleavage and polyadenylation in the 3Ј-UTR of exon 8A, which removes all GHR-specific sequences from the transcript, followed by splicing of exon 8A to exon 7 (lower right pathway in Fig. 7 ). This will be referred to as the C/S (cleavage before splicing) GHBP pathway. It has not been established whether both the S/C and C/S pathways occur in vivo or whether only one of the pathways is used. However, the observation that the ratio of hepatic GHBP to GHR transcripts increases during pregnancy (37, 102) indicates that the processing is regulated. Determining the pathway(s) that are used in GHR and GHBP transcript 
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ALTERNATIVE GH RECEPTOR TRANSCRIPTSproduction is very likely to be important in understanding how their levels are regulated. The splicing pathways that produce GHR and GHBP mRNAs were recently investigated using a GHR-GHBP minigene transfected into mouse L cells (103) . The minigene was composed of two intronless coding regions derived from the GHR cDNA (GHR exons 2-7 and 8 -10) separated by the unspliced genomic region separating exons 7 and 8 (intron 7/8A, exon 8A, and intron 8A/8; Fig. 8 ). The genomic region of the minigene contained the exon 7 splice donor site, the exon 8A and exon 8 splice acceptor sites, and the exon 8A polyadenylation consensus sequence, which together constitute the canonical cis-elements necessary for the GHR and GHBP splicing pathways. The ability of the minigene to mimic authentic GHR and GHBP splicing was confirmed by RT-PCR detection of correctly spliced GHR and GHBP transcripts in transfected cells. Incompletely spliced minigene transcripts were also observed, perhaps due to low endogenous levels of splicing factors in the cell line.
An altered form of the minigene, in which cleavage in the exon 8A 3Ј-UTR was blocked by removal of the exon 8A polyadenylation sequences, generated the GHR transcript and a GHBP-encoding transcript in which exon 8A was spliced to exon 7. Due to the elimination of cleavage in exon 8A, the GHBP-encoding transcript was assumed to retain intron 8A/8 and exons 8, 9, and 10 and therefore was larger FIG. 7. Alternative splicing pathways for generation of GHR and GHBP transcripts in mice. Exon and intron symbols are explained in the legend to Fig. 2 . The primary transcript, GHR transcript, and GHBP transcript are boxed. Exons 1-6 (which are common to GHR and GHBP transcripts) are shown as a single unit for clarity. Primary transcripts can become committed to the GHR splicing pathway (upper diagram) by splicing of exon 8 to exon 7. This removes the GHBP-specific exon 8A from the transcript. Primary transcripts can become committed to the GHBPsplicing pathway (lower diagram) by splicing of exon 8A to exon 7 followed by cleavage of the transcript in the 3Ј-UTR of exon 8A (lower left), or by cleavage of the transcript in the 3Ј-UTR of exon 8A followed by splicing of exon 8A to exon 7 (lower right).
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than GHBP transcripts found in vivo. Nevertheless, the result indicated that the first step in the S/C GHBP pathway (splicing of exon 8A to exon 7 without prior cleavage of the transcript in exon 8A) can occur in vitro.
In a parallel experiment, the mouse cell line was transfected with a minigene designed to eliminate splicing of exon 7 to exon 8A through a mutation of the exon 8A splice acceptor site. No transcripts containing exons 7 and 8A spliced together were detected by RT-PCR, indicating the mutation had successfully abolished GHBP splicing. However, in addition to GHR transcripts, cells transfected with the mutated minigene produced a transcript retaining intron 7/8A and exon 8A. Northern analysis indicated this transcript was cleaved in the 3Ј-UTR of exon 8A, demonstrating that the first step in the C/S GHBP pathway (cleavage in exon 8A without prior splicing exon 7 to 8A) can also occur in vitro.
Together, the minigene data indicated that neither exon 8A splicing nor cleavage in the 3Ј-UTR of exon 8A is absolutely dependent on the other process having occurred previously. Although this result is consistent with both the S/C and C/S pathways being able to contribute to the cellular GHBP mRNA pool, it is important to note the experiments do not indicate that both pathways occur in vivo or that both are used to equal degrees to produce GHBP mRNA. Additional experiments, designed to quantitate the transcript levels produced by the intact minigene and the mutated forms, will be necessary to estimate the contribution of each pathway in vivo.
b. Rat. Rat GHBP is also produced by alternative splicing of the GHR primary transcript (104) . The sizes of rat GHR and GHBP are similar to those of the mouse (21, 105). Two transcripts of 4.75 kb and 1.2 kb hybridized with a GHR probe in Northern blots of rat tissues (8). A cDNA clone of the 1.2-kb transcript was identical in sequence to the receptor transcript until nine bases before the hydrophobic transmembrane domain-encoding region, at which point the sequence diverged completely. Beyond the divergence point, the transmembrane and intracellular domain-encoding regions of the receptor transcript were replaced in the smaller transcript by a 17-amino acid hydrophilic domain-encoding region. Transfection of the 1.2-kb cDNA into COS-7 cells resulted in 96% of the assayable GH-binding activity being located in the medium, indicating that the smaller transcript encoded a secreted GHBP. An antibody raised against the 17-amino acid hydrophilic domain encoded by the 1.2-kb transcript immunopreciptated almost all GHBP from rat serum (106, 107) .The portion of the rat GHR gene between exon 7 and exon 8 was cloned and analyzed (104) . The GHR gene structure in this region was essentially identical with that of the mouse. The intron between exons 7 and 8 contained an exon encoding the hydrophilic domain and 3Ј-UTR of the GHBP transcript. These findings confirmed the alternative splicing hypothesis of rat GHBP generation. As with the mouse, the pathways by which the GHR and GHBP transcripts (i.e., S/C or C/S GHBP mRNA generation) are produced in vivo remain to be determined.
c. Rabbit. Studies suggest that the serum GHBP is generated in some species by proteolytic cleavage of the receptor's hormone-binding domain rather than through the alternative splicing mechanism found in mice and rats (reviewed in Ref. 28). Despite the presence of GHBP in the circulation, there have been no reports of transcripts lacking the hydrophobic transmembrane-encoding region in the human, rabbit, sheep, bovine, or pig, suggesting that in these species GHBP is produced posttranslationally. Posttranslational generation of GHBP from GHR has been best characterized in the rabbit. Previous studies demonstrated that rabbit GHR has an M r of 100,000 -130,000 (6) and the GHBP has an M r of 51,000 (108) . Transfection of the full-length rabbit GHR cDNA into CHO cells, the human hepatoma HepG2 cell line, 
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ALTERNATIVE GH RECEPTOR TRANSCRIPTSand COS-7 cells (109, 110) resulted in expression of GHR in the plasma membrane and secretion of GHBP into the culture medium. Because the transfected GHR cDNA did not contain intron sequences, it was not believed to undergo any splicing. The GHBP in the medium was therefore thought to originate from the intact receptor by proteolytic cleavage. Although no specific protease(s) involved in the cleaving reaction were identified, the fact that three cell lines of diverse tissue and species origin were able to carry out the cleavage reaction suggested that the protease(s) responsible for the cleavage have a wide pattern of expression. The exact point of receptor cleavage has not been precisely determined. Protein sequencing, however, has demonstrated that amino acids 190 -197 of the 246-amino acid rabbit GHR extracellular region are definitely present in the binding protein (6). Additional protein sequencing in the same study tentatively identified extracellular amino acids 237-239 as also being present in the binding protein, but due to weak signals their identification was not certain. Together, these data indicate that the rabbitbinding protein is produced by proteolytic cleavage of the receptor hormone binding-domain and that the cleavage site is located C-terminal to amino acid 197, possibly within a few residues of the transmembrane domain. The sequence specificity of the cleavage reaction was demonstrated by the finding that COS-7 cells transfected with rat GHR cDNA do not secrete GHBP into the medium (110), implying that the rat GHR does not contain the proper amino acid sequence for cleavage by the protease(s) responsible for rabbit GHR cleavage in COS-7 cells. d. Monkey. Transfection of the human kidney fibroblast 293 cell line with monkey GHR cDNA resulted in release of soluble GHBP into the medium as well as expression of the full-length receptor in the cell membrane, suggesting that generation of GHBP in the monkey can take place through proteolytic cleavage of the receptor (14). Like the rat and the mouse, however, the monkey also expresses an alternatively spliced GHR transcript that encodes a functional GHBP. Analysis of monkey cDNA revealed a transcript that was identical in sequence to the GHR transcript for the first 784 bases of the hormone-binding domain-encoding region but which diverged in sequence 8 bp before the beginning of the transmembrane domain-encoding region of the receptor mRNA. Downstream of the divergence point, the GHBP transcript contained 236 bp of novel sequence, which included a polyadenylation signal and terminated in a polyadenosine tail. Comparison of the monkey GHR and GHBP sequences with the human GHR genomic sequence revealed that the point at which the monkey GHBP and GHR transcripts diverged is exactly coincident with the 3Ј-end of human exon 7 and, furthermore, that downstream of the divergence point, the monkey GHBP transcript is identical in sequence to the 5Ј end of human intron 7/8. The transcript's predicted translation product would contain the first 243 amino acids of the receptor's 246-amino acid extracellular domain. The final 3 amino acids of the extracellular domain and the entire transmembrane and intracellular domains of the receptor would be replaced by 8 novel amino acids before an in-frame stop codon occurred. The similarity of the transcript's novel sequence with human intron 7/8 and the lack of a transmembrane domain in the translation product suggested to the authors that the transcript is a GHBP-encoding mRNA produced by retention of intron 7/8 (Fig. 9) . PCR analysis showed that GHBP transcript expression is highest in the stomach, intermediate in the kidney and heart, and lowest in the liver. No expression was detected in the intestine and pancreas.
Transfection of 293 cells with the GHBP cDNA resulted in secretion of GH-binding activity into the medium. There was no significant difference in the affinity constant of the GHbinding activity secreted from cells transfected with monkey GHR or GHBP cDNA, suggesting that functional monkey GHBP can be produced by proteolytic cleavage of full-length receptors and by retention of intron 7/8 in the GHR transcript. Further studies will be needed to determine the relative contributions of the GHBPs produced by proteolytic cleavage and alternative splicing to the total pool of circulating GHBP in the monkey. In addition, the same questions raised about GHBP mRNA generation in the mouse and rat are also applicable to the monkey. Is cleavage and polyadenylation upstream of exon 8 or alternative splicing to exon 7 the processing step that commits the nascent transcript to the GHBP pathway?
A second alternatively spliced GHR transcript was also detected by PCR analysis of monkey RNA. Sequencing of the PCR product revealed that the segments encoded by exons 4, 5, and 6 in the human GHR gene were deleted in the monkey transcript. Translation would result in a protein containing the signal sequence and the first 28 amino acids of the hormone-binding domain (encoded by exons 2 and 3), followed by 16 novel amino acids (encoded by a frame shifted reading of exon 7) before a stop codon is encountered. The function of the protein encoded by this transcript is not clear. The absence of a hydrophobic transmembrane domain suggests the protein would not function as membrane-bound receptor, while the absence of the amino acids critical for GH binding (reviewed in Ref. 47) suggests that it would not function as circulating GHBP. Further studies of the expression and translation of this transcript will be necessary to determine its biological significance.
e. Chicken. Western analysis has identified two major GHBPs in chicken serum. The M r of these proteins is 69,500 and 27,500 (24). The source of GHBP in the chicken, however, is not clearly understood. Although it might arise from proteolytic cleavage of GHR in a fashion analogous to that of the rabbit, there are two chicken GHR transcript variants that potentially encode GHBPs. One transcript variant is produced by the use of an alternative polyadenylation site located within the coding region of the transcript. The second transcript variant is produced by the use of an alternative 3Ј-splice acceptor site upstream of exon 7. Northern analysis of liver mRNA showed that the chicken has two mRNAs of 4.7 kb and 0.7 kb and several minor transcripts of intermediate size that hybridize to GHR probe (13, 56, 57). Sequencing of cDNA clones showed that the larger mRNA corresponded to the full-length receptor. The cDNA corresponding to the 0.7-kb mRNA contained the first 325 nucleotides of the fulllength receptor sequence followed by a polyadenosine tail. In most mRNAs, polyadenylation occurs in the 3Ј-UTR and requires two sequence motifs, a polyadenylation consensus sequence (AAUAAA) and a GU-rich region located slightly Vol. 19, No. 5 downstream of the RNA cleavage site (reviewed in Refs. 111 and 112). The coding region of the full-length chicken GHR transcript contains both of these motifs. An AAUAAA sequence occurs at nucleotide positions 304 -309, and a GU-rich sequence occurs between nucleotides 330 and 346. The authors hypothesized that the 0.7-kb transcript was produced by RNA cleavage and polyadenylation of the GHR transcript between these two sites (Fig. 10) . RT-PCR showed that turkey, duck, and quail, which also express a 0.7-kb GHR transcript, all have a polyadenylation consensus sequence and the GU-rich region at this location. Mammalian GHR-coding regions, on the other hand, do not contain a polyadenylation consensus sequence at this location. These findings suggest that truncation of the GHR transcript by polyadenylation is restricted to certain avian species.
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To further investigate the generation of the chicken 0.7-kb transcript, transfection studies were carried out in the monkey kidney CMT-3 cell line. Transfection of the cells with the full-length chicken cDNA generated both the normal and the truncated transcripts. Mutation of the AATAAA sequence to AACAAG abolished expression of the truncated transcript. Transfection with the rat GHR cDNA (which lacks the internal AATAAA sequence) produced only full-length transcripts. Lastly, a chimeric cDNA was constructed by replacing 148 bases of the rat GHR sequence with the homologous sequences from the chicken GHR, which included the AATAAA and the GT-rich sequences. Transfection with this cDNA generated normal and truncated transcripts. Together these data indicate that the sequences present in the coding region of the chicken GHR gene permit cleavage and polyadenylation of the chicken transcript in a heterologous cell type and that these sequences are sufficient to confer cleavage and polyadenylation to rat GHR transcripts, which are normally not truncated in this manner.
Although the 0.7-kb transcript was shown to be associated with polyribosomes in liver cells, indicating that it is translated, the biological properties of the truncated protein product were not investigated in the above studies. Certain predictions, however, based on the amino acid sequence encoded by the 0.7-kb mRNA, can be made. Because the truncated GHR would lack the hydrophobic transmembrane and intracellular domains of the full-length receptor, it is very unlikely that the protein is an integral membrane protein or that it could activate known GHR signal transduction pathways. Whether the translated 0.7-kb transcript encodes a functional GHBP is not clear. Only the first 95 amino acids 
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ALTERNATIVE GH RECEPTOR TRANSCRIPTSof the 221-amino acid hormone-binding domain of the receptor are encoded. The 95 amino acids that would be present in the protein include roughly half of the amino acids that have been implicated by mutagenesis (reviewed in Ref. 47) and crystallography studies (67) as being important for GH binding. Because there is no stop codon in the truncated transcript, the polyadenosine tail would be translated into a polylysine domain at the C terminus of the protein, perhaps forming a structure analogous to the hydrophilic C-terminal domain of the rat and mouse GHBPs. Purification and GHbinding studies of the truncated receptor must be undertaken to determine whether it does encode a functional GHBP. The other potential GHBP-encoding transcript in the chicken is an alternatively spliced product of the GHR gene. A clone containing a 17-bp segment inserted in between the sequences encoded by exons 6 and 7 (53) was isolated from a cDNA library. Expression of transcripts containing the insertion was confirmed by RT-PCR. Sequencing of the chicken genomic DNA showed that the inserted segment matched the sequence of the final 17 bases of intron 6/7, suggesting that the transcript was produced by use of an alternative 3Ј-splice acceptor site 17 bp upstream of exon 7 (Fig. 10) . Although the transcript contains transmembrane and intracellular domain-encoding sequences, the insertion causes a frame shift that would produce a truncated GHR protein containing the first 177 of the receptor's 221 extracellular amino acids followed by 6 novel amino acids before a stop codon is reached. The presence of 80% of the hormonebinding domain and the lack of the transmembrane and intracellular domains led the authors to hypothesize that the protein encoded by this mRNA might function as a secreted GHBP.
Truncations of the intracellular domain.
Several species express GHR transcripts with deletions or truncations in the intracellular domain-encoding region. Because the intracellular domain of the receptor is responsible for initiating signal transduction, these alterations could potentially cause an increase or decrease in the normal cellular response to GH or cause a nonstandard cellular response to GH. The first report of a GHR with alternations in the intracellular domain was made when the rabbit GHR cDNA was cloned (6). In addition to the full-length GHR cDNA, cDNAs encoding a receptor with a truncated intracellular domain were also cloned. These cDNAs encoded the full-length receptor's extracellular and transmembrane domains and the first 4 amino acids of the intracellular domain. Beyond the fourth intracellular amino acid, they encoded 4 novel amino acids (not found in full-length receptor) before a stop codon was encountered, making the intracellular domain in these transcripts a total of 8 amino acids in length (compared with the 350-amino acid intracellular domain of the full-length rabbit GHR). Exon 8 of the human GHR gene encodes the transmembrane domain and the first four amino acids of the intracellular domain. The point of divergence of the truncated rabbit clones is therefore exactly coincident with the 3Ј-end of exon 8 in the human gene, suggesting that alternative splicing involving the splice donor site of exon 8 of the rabbit gene is the mechanism by which these clones were generated.
The presence of GHR transcripts with divergent sequences in the intracellular domain was confirmed in the rabbit and detected also in humans, rats, and mice by PCR (113) . Primers complementary to sequences in human exon 7 and exon 10 were synthesized and used to amplify the region of the human GHR cDNA corresponding to exons 8 and 9. The   FIG. 10 . Generation of GHR/GHBP protein isoforms in the chicken by alternative RNA cleavage/polyadenylation and use of an alternative splice acceptor site in intron 6/7. The top portion of the diagram shows the section of the chicken GHR gene containing exons 5, 6, and 7. Exon and intron symbols are explained in the legend of Fig. 2 . Dotted diagonal lines indicate alternative splicing pathways. The striped box inside exon 5 shows the location of transcript cleavage when the alternative RNA cleavage/polyadenylation site within the coding region is used. Cleavage and subsequent polyadenylation at this site result in production of the 0.7-kb transcript. Transcripts not cleaved in exon 5 can undergo alternative splicing of exon 6 to either a splice acceptor site within intron 6/7 or to exon 7. Both of the alternatively spliced transcripts are 4.6 kb. The lower portion of the diagram shows the predicted protein products of the alternative processing pathways. Protein symbols are explained in the legend of Fig. 1 . The C-terminal domain of the 0.7-kb transcript's protein product is predicted to consist entirely of the amino acid lysine due to translation of the transcript's polyadenosine tail. The number of lysine residues in this domain is not known.
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EDENS AND TALAMANTES Vol. 19, No. 5 predicted 295-bp amplification product (i.e., full-length receptor containing exons 8 and 9) was observed. In addition, a smaller 269-bp product was also observed. Cloning and sequencing the smaller product showed that it contained a deletion of the first 26 bp of exon 9 sequence. This resulted in a frame shift that would give rise to a truncated receptor containing the first 273 amino acids of GHR (the 246-amino acid extracellular hormone-binding domain, the 24-amino acid transmembrane domain, and the first 3 amino acids of the intracellular domain), followed by 6 novel intracellular amino acids before a stop codon is read. Because the total number of amino acids in the truncated GHR protein would be 279, it will be referred to as the human GHR 279 . The proposed alternative splicing mechanism by which the GHR 279 transcript is produced is diagrammed in Fig. 11 . The splice donor site of exon 8 can be joined either to the canonical splice acceptor site at the 5Ј-end of exon 9 to generate the full-length transcript or to an alternative splice acceptor site located 26 bp within exon 9 (generating the GHR 279 transcript). The internal exon 9 splice site sequence resembles the mammalian 3Ј-splice acceptor consensus sequence (5Ј-12 (T/C)NCAG-3Ј) found at the 3Ј-end of most introns (114), further supporting the proposed alternative splicing model. The GHR 279 transcript was found to be expressed at varying levels in liver, mammary gland, adipose, placenta, lung, kidney, stomach, and muscle. In the mammary gland, adipose tissue, and placenta it was comparable in level to the fulllength transcript. In liver and kidney its levels were lower, the hepatic levels being less than 10% of that of the full-length transcript (115) . In lung, stomach, and muscle the GHR 279 transcript was barely detectable. Transcripts analogous to the human GHR 279 transcript were detected in the rabbit, mouse, and rat using the same RT-PCR method described above. The GHR 279 transcript in all three species had a deletion of the first 26 bases of exon 9, suggesting that the same alternative splicing mechanism proposed for the human transcript also operates in these species. The properties of the GHR 279 protein product were investigated by transfecting the cDNA into the 293, COS-7, and CHO cell lines (113, 115, 116) . In all cell lines the total amount of specific GH binding to the membrane and the amount of GH-binding activity in the medium increased compared with transfections of the full-length receptor. The studies in the CHO cell line demonstrated that the increase in membrane GH binding was due to lack of internalization of the truncated receptor, including both constitutive and GH-induced internalization. This finding is consistent with previous studies showing that intracellular amino acids absent in GHR 279 are necessary for ligand-mediated internalization (117, 118) . The GH-binding levels in the medium increased both in absolute terms and also when normalized to the total GH binding in the membrane fraction, suggesting that the increase was not due solely to a larger number of receptors on the cellular membrane but also to preferential cleavage of GHR 279 by the protease(s) responsible for GHBP release. The increase in GHBP generation by GHR 279 was approximately 
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ALTERNATIVE GH RECEPTOR TRANSCRIPTS4.5-fold when normalized to full-length GHR levels. Treatment of the GHR 279 -expressing CHO cells with cyclohexamide did not lower membrane GH binding or media GH binding. Because the release of GHBP into the media in the absence of protein synthesis was not accompanied by a corresponding decrease in membrane GH binding, the authors hypothesized that intracellular GHR 279 is the primary source of secreted GHBP. The affinity of GH-GHR 279 binding was measured by Scatchard analysis. Interestingly, the study in 293 cells showed that full-length GHR had 2-fold higher association constant (K a ) values than GHR 279 , while in the COS-7 cell study, GHR 279 had a 2-fold higher K a than full-length GHR. The difference in relative K a values might simply reflect variations in analysis technique or sample purity, or it might indicate actual differences in K a , perhaps due to dissimilar posttranslational modification of GHR in the two cell types.
The functional properties of the truncated receptor were tested in the 293 cell line. A luciferase reporter gene ligated to a promoter containing the binding consensus sequence for the transcription factor STAT5 was cotransfected into the 293 cells with GHR 279 or full-length GHR cDNAs. Cells transfected with full-length GHR showed a 12-fold induction in luciferase activity when stimulated by GH, indicating that the full-length receptor expressed in 293 cells was functional with regard to activating STAT5. Cells transfected with GHR 279 cDNA were unable to stimulate any increase in luciferase activity, consistent with experiments showing that the intracellular domain amino acids missing in GHR 279 are necessary for STAT5 activation (119 -121) . Simultaneous transfection with GHR 279 and full-length GHR cDNAs resulted in a lower level of luciferase activity than by transfection with full-length GHR alone, indicating that GHR 279 acts in vitro as an inhibitor of STAT5 activation by the fulllength receptor. This finding raises the possibility that GHRs with truncated intracellular domains might function in vivo as attenuators of GH signal transduction. Normal GHR signal transduction requires GH-mediated dimerization of plasma membrane GHR (reviewed in Ref. 122) . The authors hypothesized that the inhibition might be due to either GHR 279 competing with the full-length receptor for GH or to GH-mediated formation of GHR 279 /full-length GHR heterodimers that were not able to initiate signal transduction. In support of the latter mechanism of inhibition, immunoprecipitation and Western blotting revealed that the two GHR types did form heterodimers in the presence of GH.
In addition to the GHR 279 transcript described above, a related form of truncated GHR message was isolated by PCR from the same human hepatic cDNA library (115) . This transcript had a complete deletion of the exon 9 sequence with a resulting frame shift due to the direct joining of exon 8 and exon 10 sequences (Fig. 12) . Translation would produce a GHR protein with a 7-amino acid intracellular domain, which will be referred to as GHR 277 . Expression of this transcript was extremely low, being less than 1% of total GHR transcripts in the tissues examined. Although the biological Vol. 19, No. 5 properties of GHR 277 were not investigated by the authors, a possible in vivo example of its expression was documented in a report describing a patient with short stature (123) . Genetic analysis revealed that the patient was heterozygous for a mutation in the GHR gene, which deleted a portion of the exon 9 splice acceptor site. The patient expressed both the full-length GHR transcript and a truncated GHR transcript with the exon 9 sequence deleted (identical to the GHR 277 transcript described above). The patient was 3.6 sds below average height for her age, consistent with the hypothesis that GHR proteins with truncated intracellular domains can act as dominant inhibitors of GHR signal transduction. Using primers complementary to exons 7 and 10, a 1043-bp region of the full-length chicken GHR transcript containing exons 8, 9, and the majority of the exon 10 coding region was amplified by RT-PCR (13). In addition to the expected PCR product, a smaller product of approximately 750 bp was also observed in all tissues analyzed. Both the large and the small PCR products hybridized to a probe complementary to the intracellular region of the GHR transcript, confirming the specificity of the reaction. The smaller PCR product was not sequenced, and therefore the location of the Ϸ300-bp deletion was not determined. The size of the deletion is not consistent with skipping of exons 8, 9, or 8 and 9 together (which would generate deletions of approximately 90, 70, and 160 bp, respectively). Splicing of exon 9 to an internal splice acceptor site approximately 300 bp inside of exon 10, however, would account for the smaller PCR product size. Further studies will be necessary to ascertain the mechanism that generates the smaller transcript and to determine whether it encodes a GHR with a truncated intracellular domain.
EDENS AND TALAMANTES
3.
Conclusion. In summary, GHBP can be produced by proteolytic cleavage of the receptor hormone-binding domain or by alternative splicing of the GHR primary transcript. The mouse, rat, and monkey have alternatively spliced mRNAs that encode the hormone-binding domain but substitute a short C-terminal domain for the transmembrane and intracellular domains of the receptor. Transcripts encoding a form of the receptor in which the intracellular domain is truncated seven to nine amino acids beyond the transmembrane domain are expressed in humans, rabbits, rats, and mice. The human intracellular-truncated receptor binds GH with comparable affinity to the full-length GHR but cannot initiate signal transduction. Its expression increases GHBP secretion from transfected cells and appears to attenuate GHR signal transduction when coexpressed with the full-length receptor.
C. Deletions in the hormone-binding domain-encoding region
There have been many documented cases of loss of GH binding due to mutations in the extracellular hormone-binding domain of human GHR (124 -126) , indicating that changes in this domain have the potential to alter the receptor's affinity for GH and hypothetically to alter its specificity for related hormones. The discovery of a common alternatively spliced GHR transcript containing a deletion in the hormone-binding domain (81) was therefore of great interest.
Restriction enzyme analysis of GHR cDNAs isolated from a human placental library indicated there were two GHR cDNA sizes present. Sequencing showed the larger cDNA corresponded to the full-length GHR transcript. The smaller cDNA was identical in sequence to the larger cDNA except for a deletion of 66 bases in the hormone-binding domainencoding region. The missing bases corresponded precisely to the 66 bases encoded by exon 3 in the human GHR gene. The exact coincidence of the deleted sequence with the exon 3 sequence suggested that the transcript was produced by an alternative splicing mechanism in which the splice donor site of exon 2 was joined to the splice acceptor site of exon 4 to produce exon 3-deleted (d3) GHR transcripts (Fig. 13) . Several groups have subsequently investigated d3 transcripts using RT-PCR to amplify the portion of the GHR cDNA normally containing exon 3 (70, 71, 81, 127, 128) . Expression of the d3 transcript was found in a wide variety of tissue types and human-derived cell lines, indicating that the d3 transcript is a common GHR transcript variant. Two of the groups reported that the ratio of d3 to full-length transcripts varied in a tissue-specific manner, while three groups found the d3/full-length ratio did not change from tissue to tissue but found, instead, that the amount of the d3 transcript varied from individual to individual. A possible explanation for this discrepancy is that the groups that reported tissuespecific expression used tissues obtained from different individuals, and therefore individual-specific differences had the appearance of being tissue-specific differences. A recent study supports the individual-specific expression model (129) . Using pedigree analysis and the PCR method described above, the authors found that the expression of the two GHR transcripts was consistent with simple Mendelian inheritance of two codominant GHR alleles. One allele produces only full-length transcripts, and the other produces only d3 transcripts. Heterozygous individuals express both transcripts, and homozygous individuals express only one of the two types. The authors found that roughly 10% of the population was homozygous for the d3-producing allele. Analysis of a monkey cDNA library by PCR revealed transcripts in which exon 3 was not present (14), while PCR analysis of hepatic GHR transcripts from fetal sheep and hepatic and placental GHR transcripts from mice did not detect any deletions in the homologous region (55, 130) . These data indicate that deletion of exon 3 occurs in a speciesspecific manner.
Because the number of bases encoded by exon 3 (66 bases) is divisible by 3, no frame shift occurs during translation of the d3 transcript. The result is that the d3 GHR lacks 22 amino acids (residues 7-28) of the hormone-binding domain and has a single amino acid substitution (alanine to aspartate) but is otherwise identical to the full-length receptor. The biological properties of the d3 receptor were examined by expression in an in vitro rabbit reticulocyte translation system, Xenopus oocytes (69), COS-7 cells (70) , primary hepatocytes, and hepatoma cells (71) . No differences were detected between the full-length and the d3-receptor in affinity for GH, or for the related hormones GH-V (a placentally produced GH variant), placental lactogen, and PRL. GH-binding activity was found in the media as well as the membranes of cells transfected with the d3-receptor, demonstrating that the
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ALTERNATIVE GH RECEPTOR TRANSCRIPTSdeletion does not eliminate production of GHBP by proteolytic cleavage. The possibility that the missing amino acids in the d3 receptor might affect the signal transduction of the receptor remains to be investigated.
IV. Summary of GHR Alternative Processing and Possible Future Studies
It is clear that the GHR gene is capable of generating a diverse group of mRNA species by alternative processing of the primary transcript. The mechanisms by which distinct transcripts are generated include use of alternative promoters, exon skipping, mutually exclusive exons, use of alternative polyadenylation sites, use of alternative splice-acceptor sites, and retention of introns. Clear differences in function of the alternatively processed transcript products are seen in some cases (such as the alternatively spliced 1.2-kb transcript that generates GHBP in the mouse), while in other cases no clear role for the variant transcript has been established (such as the 0.7-kb chicken transcript) or no functional difference between the alternative transcript and the full-length transcript have been found (such as the deletion of exon 3 from human and monkey transcripts).
Future research in GHR molecular biology will undoubtedly rely on RT-PCR as well as traditional cDNA cloning to fully characterize GHR transcripts. The necessity of using both methods is illustrated by the characterization of human GHR cDNA. The original cloning (6) was accomplished by conventional cDNA library screening. Subsequent RT-PCR studies, using primers based on the published cDNA sequence, revealed several alternatively spliced forms of the transcript that were not found in the sequencing of the original cDNA clones, including deletion of exon 3 (81), partial deletion of exon 9 (113, 115) , full deletion of exon 9 (115), and three of the eight known 5Ј-UTRs (77). These findings suggest that the heterogeneity of GHR transcripts is best analyzed by RT-PCR and that obtaining a cDNA sequence should be viewed as only the initial step in transcript analysis. Consequently, a comprehensive PCR-based reevaluation of the nine cloned GHR transcripts is in order, using mRNA collected from a variety of tissues and physiological states. This undertaking would have the potential to uncover novel forms of the transcript, to characterize the tissue and physiological state-specific expression patterns of individual 5Ј-UTRs, and to determine the cross-species distribution of known alternative GHR forms.
In addition to thorough PCR analysis of GHR transcripts, cloning of the GHR gene from additional species is also a potential source of important findings. Specifically, characterization of the gene structure can reveal the mechanism by which alternative GHR transcripts are generated (i.e., skipped exon, internal splice acceptor site, retained intron, etc.) and allow specific regions of the gene to be analyzed for functional cis-acting sequence elements. Examples of the lat- Vol. 19, No. 5 ter include promoter analysis of the GHR-regulatory regions (52, 62, 63, 83) and studies of alternative splicing regulation by mutation of splice sites and other cis-elements involved in transcript processing (103) . Lastly, the biological significance of the various alternative receptor transcripts (including the binding protein) remains largely unexplored. Most studies in this area have relied on in vitro expression of transfected cDNAs to characterize the GH-binding, GHBP-secretion, and signal transduction properties of the proteins encoded by full-length and alternative GHR transcripts. As the feasibility and precision of creating transgenic and gene knock-out animals increases, the in vitro studies will undoubtedly be complemented and extended by studies investigating the in vivo effects of different GHR transcript forms. As an example of this approach, a strain of mice with a disrupted GHR gene has recently been generated (131) . A portion of exon 4 and intron 4/5 was removed from the GHR gene in embryonic stem cells by homologous recombination. Mice homozygous for the disrupted gene had no detectable hepatic GHR or GHBP transcripts, no hepatic GHR protein, and no detectable serum GHBP. The abnormalities displayed by the mice included decreased postnatal growth, delayed sexual maturation, and production of fewer offspring. Future studies undoubtedly will involve selectively altering the GHR gene to eliminate specific types of alternative splicing while leaving expression of the fulllength GHR unchanged. For example, it has been shown that use of the alternative splice acceptor site located within exon 9 produces truncated GHRs that inhibit the cellular response to GH in vitro (113, 115) . The possibility that the truncated receptor functions in vivo as an inhibitor of GH response could be addressed directly by observing the phenotype of transgenic and gene knock-out animals engineered to express either increased amounts of the truncated receptor or only the full-length receptor. In a similar manner, the in vivo role of the circulating binding protein might be addressed through transgenic animals in which GHBP expression has been either abolished or increased above normal concentrations. In species in which GHBP is potentially generated from more than one transcript type (such as the chicken and the monkey), this approach could be used to determine the relative contribution of each transcript type to the GHBP pool by altering the gene to eliminate the splicing pathways leading to one of the transcript types. 
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